ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
Stocks · News reference
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ArriVent BioPharma shares are trading lower after the company announced its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant NSCLC failed to meet its primary endpoint of progression-free survival.
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
Dow Jumps 200 Points; US Trade Deficit Widens In August
U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. Utilities gained; energy and oil fell.